Design Therapeutics (DSGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.34
- EPS estimate
- −$0.33
- EPS surprise
- −3.03%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 7, 2025
Design Therapeutics' most recent results in the table are for Q2 2025, reported on August 7, 2025. It posted a loss of $0.34 per share, against an expected loss of $0.33, a miss of 3.03%. That loss was about 62% wider than the $0.21 per share lost in Q2 2024. No revenue is shown for any quarter in the table, and no revenue estimate was given.
All 18 quarters in the table, from Q1 2021 to Q2 2025, were losses. Full-year losses were $0.86 per share in 2021, $1.14 in 2022, $1.20 in 2023 and $0.88 in 2024. The first half of 2025 adds up to a loss of $0.65, against $0.41 in the first half of 2024. Quarterly losses ranged from $0.14 in Q2 2021 to $0.36 in Q2 2023. Design Therapeutics beat the EPS estimate in 11 of the 18 quarters, including a run of nine straight from Q4 2022 to Q4 2024, then missed in both quarters of 2025.
The table holds no results after Q2 2025, so later quarters are not shown. In earlier years, Q3 results came in early-to-mid November and Q4 results in March. The next update will show whether losses kept widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$0.33 | −$0.34 | −3.03% | $0.00 | SEC |
| Q1 2025 | May 7, 2025 | −$0.28 | −$0.31 | −10.71% | $0.00 | SEC |
| Q4 2024 | Mar 10, 2025 | −$0.27 | −$0.24 | +10.01% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.24 | −$0.23 | +5.47% | $0.00 | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.23 | −$0.21 | +9.99% | $0.00 | SEC |
| Q1 2024 | May 8, 2024 | −$0.26 | −$0.20 | +24.04% | $0.00 | SEC |
| Q4 2023 | Mar 19, 2024 | −$0.31 | −$0.21 | +32.26% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$0.41 | −$0.28 | +31.29% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.40 | −$0.36 | +9.43% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.36 | −$0.35 | +2.23% | $0.00 | SEC |
| Q4 2022 | Mar 14, 2023 | −$0.34 | −$0.31 | +9.88% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.29 | −$0.32 | −11.11% | $0.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.25 | −$0.27 | −8.00% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.22 | −$0.24 | −9.09% | $0.00 | SEC |
| Q4 2021 | Mar 10, 2022 | −$0.23 | −$0.20 | +11.78% | $0.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.14 | −$0.21 | −50.00% | $0.00 | SEC |
| Q2 2021 | Aug 9, 2021 | −$0.18 | −$0.14 | +22.22% | $0.00 | SEC |
| Q1 2021 | May 10, 2021 | −$0.24 | −$0.31 | −30.97% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Design Therapeutics (DSGN) last report earnings?
Design Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did DSGN beat earnings estimates?
No. Design Therapeutics reported EPS of −$0.34 for Q2 2025 against a −$0.33 estimate — a 3.03% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.